Mucormycosis Market Share

Mucormycosis Market Scenario:

The mucormycosis market is projected to reach USD 997.93 Million by 2030 at 8.4% CAGR during the forecast period 2022-2030.Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. There are approximately 1.5 million different species of fungi on the earth, however, only around 300 are responsible for causing diseases and infections in humans. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.  

These infections need to be treated with prescribed antifungal medication, usually amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally. Often, mucormycosis requires surgery to remove the infected tissue.

The prognosis of mucormycosis is usually poor. It depends on various factors such as the overall health of the patient and ability to respond to treatments, the speed of diagnosis, and treatment provided. For instance, the mortality rate with rhinocerebral and GI mucormycosis is about 85% while the mortality rate for patients with other types of mucormycosis is about 50%. Patients who survive this infection often end up having disabilities such as blindness, limb loss, organ dysfunctions among others.

The market growth is mainly driven by increasing prevalence of fungal infections, availability of wide range of products, and rising incident of immunological diseases. Moreover, increasing awareness about fungal infection and increasing government support for research & development have fuelled the market growth. However, side effects of the treatment and presence of misbranded and spurious drugs may slow the growth of the market. There are a number of medicines available in the market for the treatment of fungal infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions, and pessaries.

Rising incidence of immunological diseases and availability of a wide range of products has driven the growth of the  mucormycosis market. Furthermore, rising geriatric population, increasing government support, and increasing healthcare expenditure have fueled the growth of the market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of the market.

A serious but uncommon fungal infection known as mucormycosis, commonly called zygomycosis, is brought on by a class of molds called mucormycetes. Fungal spores in the air can also harm the lungs and sinuses when inhaled. The fungus can also enter the skin from wounds caused by burns, scrapes, cuts, or other skin injuries. Anybody can have a fungal infection, but those with compromised immune systems are more likely to get one, and it can happen almost anywhere on the body. Opportunities for market growth are created by the rise in the number of pharmaceuticals prescribed for the global mucormycosis market distributed through retail pharmacies and the rise in the number of retail pharmacies in developed nations. In addition, customers favor shopping in retail pharmacies. A rise in the quantity of R&D activities is another factor driving the market's expansion.

The global market for infections with Flavimonas oryzihabitans will benefit from these opportunities. The government sponsors research and development (R&D) activities to entice scientists and pharmaceutical businesses to create novel medications. In addition, mucormycosis risk factors include organ transplant, malignancy, diabetes that is uncontrolled, neutropenia, and neutropenia. According to the degree of tissue involvement, mucormycosis symptoms vary, but common ones include discomfort, fever, sinus pain, and organ cellulitis. The level of tissue involvement determines the symptoms of mucormycosis, which typically include discomfort, fever, sinus pain, and organ cellulitis. The prevalence of this condition is increasing, and crucial diagnostic techniques and therapies will spur market expansion. During the projected period, it is anticipated that increasing agreements by the key market participants to produce anti-fungal drugs in the medical management of mucormycosis will accelerate market expansion.

News:

A team of doctors and scientists working together in Kolkata has discovered the cause of the mucormycosis, or black fungus, that killed thousands of people during the Covid-19 pandemic and infected a portion of the patients. The observational investigation led the research team to conclude that "deficient myeloid phagocytic function" was a key factor in the development of black fungus. The results were released in journals of the American Society for Microbiology. During the second wave, at least 150 instances of mucormycosis related to Covid were reported in Bengal. It was discovered that patients who had mucormycosis after receiving Covid had acute infections that required lengthy critical care, including long oxygen support and steroid therapy. Up until now, it was thought that uncontrolled diabetes, oxygen, and steroid medication, exposure to the environment, and immunological dysregulation were the main risk factors for patients to acquire Covid-associated mucormycosis.

Intended Audience:

• Mucormycosis Drug Suppliers


• Mucormycosis Drug Manufacturers


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Academic Medical Institutes and Universities

Segmentation:

The mucormycosis market is segmented on the basis of species, diagnosis, treatment, and end-users.

On the basis of the species, the mucormycosis market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others.

On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.

On the basis of the treatment, the mucormycosis market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs is further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.

On the basis of the end-user, the mucormycosis market is segmented into hospitals & clinics, medical institutes, research organization, and others.

News

The mucormycosis market is divided into several categories according to the species, including Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, among others. Depending on the diagnosis, the market is divided into computed tomography (CT), magnetic resonance imaging (MRI), tissue biopsy, and other categories. The mucormycosis market is divided into surgical procedures, anti-fungal medications, amphotericin B therapy, and other treatments. Posaconazole, isavuconazole, voriconazole, fluconazole, flucytosine, and other antifungal medications are further categorized. The mucormycosis market is divided into hospitals & clinics, healthcare institutes, research organizations, and others based on the end user.

Regional Analysis:                     

The mucormycosis market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas dominate the mucormycosis market owing to a well-developed healthcare sector and huge patient population for mucormycosis. Many antifungal drugs have lost their patients during the last few years such as Terbinafine products like Lamisil lost their patient in 2017. As there is limited oral preparation in the market, development and licensing of new drugs in the market is the huge opportunity for the development of the market during the forecasted period.

Europe is the second largest market for the global mucormycosis owing to the advancements in the technology of the surgical devices along with the rising occurrence of fungal infections among the patients. The European government introduced incentives to help simplify the improvement of anti-infective drugs and dropping the risk and cost of manufacturers. Some other factors driving the market include the growing percentage of diabetes mellitus population mainly in the developed countries of Europe. The average diabetes prevalence rate in Europe is 8.6% of the adult population.

Asia Pacific is the fastest growing region for antifungal treatment due to increasing prevalence of HIV, and huge untapped growth opportunities for the development of the market. Every year, approximately 7.1% of the Korean population receives treatment for fungal diseases. Therefore, further research is needed to understand and monitor the prevalence of mycoses to establish management policies to reduce the burden of fungal diseases.

While the Middle East & Africa had the lowest share in antifungal treatment market, in 2016.

Key Players:

Some of key the players in the mucormycosis market are Abbott Laboratories (U.S.), Biocon Limited (India),  Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland),   Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others